Security Snapshot

ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT) Institutional Ownership

CUSIP: H0036K147

13F Institutional Holders and Ownership History from Q2 2020 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

114

Shares (Excl. Options)

82,866,357

Price

$3.53

Type / Class
Equity / Common Shares, par value CHF 0.08 per share
Symbol
ADCT on NYSE
Shares outstanding
128,210,515
Price per share
$3.76
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
82,866,357
Total reported value
$292,847,531
% of total 13F portfolios
0%
Share change
+14,892,279
Value change
+$51,266,770
Number of holders
114
Price from insider filings
$3.76
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Sponsored

Quick Takeaways

  • ADCT - ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share is tracked under CUSIP H0036K147.
  • 114 institutions reported positions in Q4 2025.
  • 8 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 114 to 2 between Q4 2025 and Q1 2026.
  • Reported value moved from $292,847,531 to $56,534.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Official SEC Source

Backed by Form 13F

Ownership context comes from SEC Form 13F and, when available, Schedule 13D/13G filings.

See Original Filing

Investment Quick Answers

What is CUSIP H0036K147?
CUSIP H0036K147 identifies ADCT - ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Redmile Group, LLC 9.9% -22% $61,941,064 -$14,512,583 12,692,841 -19% Redmile Group, LLC 06 Apr 2026
TCG Crossover GP II, LLC 9.2% $42,143,648 11,390,175 TCG Crossover GP II, LLC 27 Oct 2025
HPWH TH AG 9.6% $14,291,858 9,788,944 Dr. Hans-Peter Wild 15 May 2025
Prosight Management, LP 6.8% +17% $31,366,151 +$4,743,267 8,477,338 +18% Prosight Management, LP 31 Dec 2025
Point72 Asset Management, L.P. 4% -43% $18,554,083 -$10,422,190 5,014,617 -36% Point72 Asset Management, L.P. 31 Dec 2025
BlackRock, Inc. 5% -4% $7,173,203 -$144,108 4,913,153 -2% BlackRock, Inc. 31 Mar 2025
Oaktree Capital Group Holdings GP, LLC 4.1% $18,693,764 4,673,441 Oaktree Fund Administration, LLC 30 Sep 2025
ORBIMED ADVISORS LLC 2.6% -25% $11,953,949 -$765,959 3,230,797 -6% ORBIMED CAPITAL LLC 31 Dec 2025

As of 31 Dec 2025, 114 institutional investors reported holding 82,866,357 shares of ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT). This represents 65% of the company’s total 128,210,515 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT) together control 60% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Redmile Group, LLC 12% 15,666,731 0% 4.1% $55,303,560
TCG Crossover Management, LLC 8.9% 11,390,175 +719% 1.3% $40,207,318
Prosight Management, LP 6.6% 8,477,338 +13% 6.2% $29,925,003
ORBIMED ADVISORS LLC 4.5% 5,822,854 -1.4% 0.44% $20,554,675
Nantahala Capital Management, LLC 4.3% 5,475,433 +142% 1.2% $19,328,279
BlackRock, Inc. 4.2% 5,427,309 +20% 0% $19,158,401
Point72 Asset Management, L.P. 3.9% 5,014,617 -38% 0.03% $17,701,598
MORGAN STANLEY 2.9% 3,769,743 +2.7% 0% $13,307,192
EVENTIDE ASSET MANAGEMENT, LLC 2.6% 3,364,067 0.19% $11,875,157
GOLDMAN SACHS GROUP INC 1.3% 1,640,872 +2.9% 0% $5,792,278
STATE STREET CORP 1.1% 1,407,325 +8.6% 0% $4,967,857
BANK OF AMERICA CORP /DE/ 1% 1,298,584 -4.6% 0% $4,584,002
VANGUARD GROUP INC 0.88% 1,129,587 +90% 0% $3,987,442
GEODE CAPITAL MANAGEMENT, LLC 0.78% 996,523 +15% 0% $3,517,725
PLATINUM INVESTMENT MANAGEMENT LTD 0.77% 990,778 -14% 0.81% $3,497,446
BNP PARIBAS FINANCIAL MARKETS 0.65% 830,903 0% 0% $2,933,088
Blue Owl Capital Holdings LP 0.57% 733,568 0% 0.91% $2,934,272
Vantage Consulting Group Inc 0.53% 682,998 0% 12% $2,410,983
PANAGORA ASSET MANAGEMENT INC 0.46% 594,256 +9.2% 0.01% $2,097,724
ACADIAN ASSET MANAGEMENT LLC 0.41% 528,965 +133% 0% $1,860,000
STEMPOINT CAPITAL LP 0.39% 502,570 +77% 0.3% $1,774,072
JPMORGAN CHASE & CO 0.37% 471,693 +43% 0% $1,665,076
Voleon Capital Management LP 0.36% 464,159 +560% 0.04% $1,638,481
NORTHERN TRUST CORP 0.34% 437,551 +4.8% 0% $1,544,556
SCHRODER INVESTMENT MANAGEMENT GROUP 0.33% 418,782 0% $1,465,737

Institutional Holders of ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 14,962 $56,534 +$10,179 $3.76 2
2025 Q4 82,866,357 $292,847,531 +$51,266,770 $3.53 114
2025 Q3 68,158,412 $272,625,712 -$9,526,921 $4.00 105
2025 Q2 67,952,003 $182,114,158 +$35,606,077 $2.68 84
2025 Q1 54,846,167 $77,332,587 -$2,528,133 $1.41 82
2024 Q4 56,494,277 $112,422,732 -$3,041,138 $1.99 82
2024 Q3 54,883,537 $172,881,709 +$3,394,419 $3.15 76
2024 Q2 51,801,951 $163,693,841 +$51,364,315 $3.16 73
2024 Q1 34,683,534 $155,728,721 +$7,168,355 $4.49 36
2023 Q4 33,953,461 $56,361,695 -$3,915,509 $1.66 36
2023 Q3 39,458,503 $35,390,528 -$10,272,333 $0.90 40
2023 Q2 45,357,348 $97,515,460 -$1,939,928 $2.15 55
2023 Q1 46,611,135 $90,890,151 +$6,156,453 $1.95 57
2022 Q4 38,834,584 $149,117,927 +$3,712,534 $3.84 59
2022 Q3 36,621,247 $176,523,672 +$9,038,590 $4.82 60
2022 Q2 34,475,113 $274,062,429 +$4,571,679 $7.95 52
2022 Q1 34,123,674 $501,279,862 +$2,970,760 $14.69 44
2021 Q4 33,799,357 $682,750,000 +$19,180,842 $20.20 50
2021 Q3 32,792,604 $890,647,136 -$45,594,727 $27.16 51
2021 Q2 33,533,099 $816,251,800 +$17,173,667 $24.35 53
2021 Q1 32,826,058 $801,283,858 +$19,636,706 $24.41 55
2020 Q4 32,141,073 $1,028,835,000 +$31,200,598 $32.01 51
2020 Q3 28,226,306 $921,776,783 +$216,837,760 $32.99 51
2020 Q2 21,557,623 $1,000,339,109 +$1,000,339,111 $46.81 41

Sponsored